S. 5052

S. 5052: A bill to address the health of cancer survivors and unmet needs that survivors face through the entire continuum of care from diagnosis through active treatment and posttreatment, in order to improve survivorship, treatment, transition to recov

Introduced Amy Klobuchar (D) SENATE_BILL — 119th Congress
Plain English Summary

S. 5052 is a bill aimed at improving the health and well-being of cancer survivors. It focuses on addressing the various unmet needs that survivors encounter throughout their journey, from diagnosis and active treatment to post-treatment recovery. The bill seeks to enhance survivorship care and ensure that survivors receive comprehensive support during their transition to recovery.

Positive Media Summary

Media coverage has highlighted the importance of S. 5052 in recognizing the ongoing challenges faced by cancer survivors. Advocates praise the bill for its comprehensive approach to survivorship care, emphasizing that it could lead to better health outcomes and quality of life for those affected by cancer. Supporters believe that addressing these needs is crucial for improving the overall healthcare system for cancer patients.

Negative Media Summary

Critics of S. 5052 have expressed concerns about the potential implementation challenges and the adequacy of funding to support the proposed initiatives. Some believe that the bill may not go far enough in addressing systemic issues within cancer care and survivorship programs. There are also worries that without clear guidelines and resources, the bill's objectives may not be effectively realized.

Conflict of Interest Analysis Deep Analysis
2/10
Risk Level
Low
Total Donations
$0
PAC Percentage
0%
Policy Area
Health

The analysis of bill S. 5052, which focuses on improving the health and care of cancer survivors, reveals no direct industry overlaps between the bill's subject matter and the sponsor, Amy Klobuchar's, top donor industries. While there is significant lobbying activity in the healthcare sector, particularly from CorMedix Inc. with a contribution of $220,000, it does not directly correlate with the specific provisions of the bill aimed at cancer survivorship. The absence of direct financial ties between the sponsors' donors and the bill's focus suggests a low risk of conflict of interest. Voters should be aware that while lobbying exists, it does not imply a direct influence on the legislation in question.

Lobbying Activity — Who's Pushing?

Organizations that lobbied on issues related to this bill's policy area.

Client Lobbying Firm Amount
CORMEDIX INC. CORMEDIX INC. $220,000
BATTELLE MEMORIAL INSTITUTE BATTELLE MEMORIAL INSTITUTE $180,000
TELECOMMUNICATIONS INDUSTRY ASSOCIATION TELECOMMUNICATIONS INDUSTRY ASSOCIATION $70,000
TERRANOVA INC FRONTERA GROUP $30,000
POSEIDON AEROSPACE FRONTERA GROUP $30,000
OBSIDIA SEMICONDUCTORS FRONTERA GROUP $20,000
SAALEX CORPORATION FRONTERA GROUP $20,000
HERTHA METALS FRONTERA GROUP $15,000
MN8 ENERGY LLC MN8 ENERGY LLC $15,000
AMERICAN LIBRARY ASSOCIATION A LEARNED HAND, LLC $10,860
RISK AND INSURANCE MANAGEMENT SOCIETY MCINTYRE & LEMON, PLLC $10,000
VERMONT CAPTIVE INSURANCE ASSOCIATION MCINTYRE & LEMON, PLLC $8,000
AMERICAN TRAILER MANUFACTURERS COALITION WILEY REIN LLP undisclosed
UNCAC COALITION UNCAC COALITION undisclosed
CFA INSTITUTE CFA INSTITUTE undisclosed

Source: Senate Lobbying Disclosure Act (LDA) filings, 2026

Sponsor's Top Donor Industries

Top industries funding Amy Klobuchar, ranked by total contributions.

Health Professionals $2,147,483,647
Individuals: $2,147,483,647 PACs: $0
Retired $737,500,000
Individuals: $737,500,000 PACs: $0

Source: OpenSecrets.org (Center for Responsive Politics)

TheBillRoom is free and independent. No ads, no subscriptions, no political funding. If this analysis was useful, reader support keeps it running.
Support Us